No two classes of biosimilars: Urgent advice to the US Congress and the FDA.

The US Congress is requested to remove the interchangeability clause from the Biological Price and Competition Act to enable faster acceptance of biosimilars and remove the threat of lack of confidence in the safety of biosimilars.